BRCA2 and breast cancer: Interestingly, RRBM-RRBSO or only RRBSO was the most effective prevention strategy in patients with luminal breast cancer aged over 35 years with the BRCA2 pathogenic variant in exons 12-25 in stage II and in patients aged over 49 years with the BRCA2 pathogenic variant in exons 1-10 in stage II.